Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV003145022 | SCV003832367 | uncertain significance | not provided | 2020-07-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004246121 | SCV004928074 | uncertain significance | Inborn genetic diseases | 2023-12-17 | criteria provided, single submitter | clinical testing | The c.2364C>G (p.C788W) alteration is located in exon 22 (coding exon 22) of the CLCN2 gene. This alteration results from a C to G substitution at nucleotide position 2364, causing the cysteine (C) at amino acid position 788 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005036676 | SCV005665013 | uncertain significance | Epilepsy, idiopathic generalized, susceptibility to, 11; Familial hyperaldosteronism type II; Leukoencephalopathy with mild cerebellar ataxia and white matter edema | 2024-06-13 | criteria provided, single submitter | clinical testing |